Q2 2025 EPS Estimates for Jazz Pharmaceuticals plc Lifted by Analyst (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) – Analysts at Zacks Research lifted their Q2 2025 earnings per share (EPS) estimates for Jazz Pharmaceuticals in a note issued to investors on Monday, October 14th. Zacks Research analyst S. Ganoria now expects that the specialty pharmaceutical company will earn $4.09 per share for the quarter, up from their prior forecast of $4.08. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.03 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals’ Q3 2025 earnings at $4.35 EPS, FY2025 earnings at $16.12 EPS, Q1 2026 earnings at $3.77 EPS, Q2 2026 earnings at $4.33 EPS and Q3 2026 earnings at $4.67 EPS.

JAZZ has been the topic of several other research reports. Piper Sandler dropped their price target on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a report on Thursday, August 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $205.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday, September 10th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Finally, JPMorgan Chase & Co. upped their price objective on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $173.14.

Jazz Pharmaceuticals Stock Up 5.6 %

NASDAQ JAZZ opened at $117.28 on Tuesday. The company has a market capitalization of $7.40 billion, a P/E ratio of 24.18, a PEG ratio of 1.34 and a beta of 0.57. Jazz Pharmaceuticals has a 12 month low of $99.06 and a 12 month high of $137.38. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02. The company’s 50 day simple moving average is $110.59 and its 200 day simple moving average is $109.76.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $3.80 by $0.87. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the sale, the senior vice president now owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.20% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Rise Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 2,255.6% in the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after buying an additional 203 shares during the last quarter. Versant Capital Management Inc lifted its holdings in Jazz Pharmaceuticals by 13,450.0% in the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 269 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new stake in Jazz Pharmaceuticals in the 2nd quarter worth approximately $29,000. EverSource Wealth Advisors LLC boosted its position in Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 97 shares during the period. Finally, GAMMA Investing LLC grew its holdings in Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 116 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.